Meeting
2019 ASCO Annual Meeting
Update on lower-dose dasatinib 50 mg daily as frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP).
Authors
Kiran Naqvi
The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX
Kiran Naqvi , Elias Jabbour , Jeffrey A Skinner , Kristin N Anderson , Musa Yilmaz , Nitin Jain , Alessandra Ferrajoli , Prithviraj Bose , Philip A. Thompson , Yesid Alvarado , Koichi Takahashi , Jan Andreas Burger , Gautam Borthakur , Zeev Estrov , Naveen Pemmaraju , Shilpa Paul , Sara Dellasala , Jorge E. Cortes , Hagop M. Kantarjian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Chronic Leukemia—CML
Clinical Trial Registration Number
NCT02689440
Citation
J Clin Oncol 37, 2019 (suppl; abstr 7052)
DOI
10.1200/JCO.2019.37.15_suppl.7052
Abstract #
7052
Poster Bd #
427
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Two-year follow-up from DASISION.
First Author: H. Kantarjian
Poster
2014 ASCO Annual Meeting
One-year and longer-term molecular responses to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: A matching-adjusted indirect comparison.
First Author: James E. Signorovitch
Poster
2013 ASCO Annual Meeting
Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): Landmark analysis of 4-year (y) data from ENESTnd.
First Author: Giuseppe Saglio
Poster
2013 ASCO Annual Meeting
EPIC: A phase III randomized, open-label study of ponatinib versus imatinib in adult patients with newly diagnosed chronic myeloid leukemia in chronic phase.
First Author: Jeffrey H. Lipton